文献速递脊柱外科

选择性保留细胞技术获取骨髓间充质干细胞浓缩液在后路腰椎融合术后的长期影像学与临床结局

Long-term Radiological and Clinical Outcomes After Using Bone Marrow Mesenchymal Stem Cells Concentrate Obtained With Selective Retention Cell Technology in Posterolateral Spinal Fusion.
PubMed 文献 · Spine (Phila Pa 1976) · 2017-01-01

回顾性研究评估选择性细胞保留技术(Cellect)联合胶原支架(Healos)获取的骨髓间充质干细胞浓缩液用于后路腰椎融合的长期结局。21例患者均实现成功融合,CT示所有患者双侧桥接骨(I级),1例1个节段单侧桥接骨(II级)。作者认为该技术可考虑作为增强脊柱融合的有效手段。

要点

  • 21例患者均实现成功融合,CT示所有患者双侧桥接骨(I级)。
  • 1例患者在1个节段检出单侧桥接骨(II级)。
  • 节段Cobb角平均差异0.48°(范围0.3°-0.7°),VAS 4.1±2.1,ODI 10.5±5.6分。

核心结论

  • 使用选择性细胞保留技术获取的骨髓间充质干细胞浓缩液可考虑作为增强脊柱融合的有效手段。
  • 证据等级为3级。

研究设计与样本

  • 回顾性研究,回顾医院记录并联系已识别患者进行临床和影像学随访评估。
  • 共纳入21例患者。
  • 临床结局采用背痛视觉模拟量表(VAS)、Oswestry功能障碍指数(ODI)和EQ-5D生活质量问卷评估。
  • 影像学结局通过动态屈伸侧位片计算节段Cobb角评估,并报告任何植入物相关并发症,同时行计算机断层扫描(CT)。

主要发现

  • 21例患者均实现成功融合。
  • 节段Cobb角平均差异为0.48°(范围0.3°-0.7°)。
  • CT扫描显示所有患者双侧桥接骨牢固融合(I级),但1例患者在1个节段检出单侧桥接骨牢固融合(II级)。
  • 患者平均在3.5个月内开始恢复工作活动。
  • 残余背痛VAS评分为4.1±2.1,ODI为10.5±5.6分,平均功能障碍指数为21.1%。

关键数值与推荐

  • 融合成功:21例患者均实现成功融合。
  • CT融合分级:所有患者双侧桥接骨(I级),1例患者1个节段单侧桥接骨(II级)。
  • 节段Cobb角平均差异0.48°(范围0.3°-0.7°)。
  • VAS评分4.1±2.1,ODI 10.5±5.6分,平均功能障碍指数21.1%。
  • 恢复工作活动平均时间3.5个月。

临床怎么用

  • 作者认为,使用选择性细胞保留技术获取的骨髓间充质干细胞浓缩液可考虑作为增强脊柱融合的有效手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective study. OBJECTIVE: The aim of this study was to evaluate the long-term clinical and radiological outcomes of the use of bone marrow mesenchymal stem cell concentrate obtained with selective cell retention technology using Cellect with a particular collagen scaffold, Healos for posterolateral spinal fusion. SUMMARY OF BACKGROUND DATA: With the increasing rate of spinal fusion, the problem of pseudarthrosis, which contributes to recurrent pain with patient disability, is considered to be the most common cause of revision lumbar spine surgery. Intensive research is being carried out to develop an alternative source of bone grafting and improve the spinal fusion rate. METHODS: A retrospective review of hospital records was performed. Identified patients were contacted to have a clinical and radiological evaluation follow-up. Clinical outcome was evaluated using visual analog scales for the back pain (VAS), Oswestry Disability Index (ODI) scores, and quality of life (EQ-5D) questionnaire. Radiological outcome was evaluated by performing dynamic flexion/extension lateral views and calculation of segmental Cobb angle. Any implant-associated complication was reported. Computed tomography (CT) scans were also performed. RESULTS: Twenty-one patients were included and all patients achieved successful fusion. The mean difference of the segmental Cobb angle was 0.48° (range 0.3°-0.7°). Computed tomography scans showed solid bilateral fusion with bridging bone (Grade I) in all patients, but solid unilateral fusion with bridging bone (Grade II) was detected for one patient at one level. Patients started to resume working activities within a mean period of 3.5 months. The VAS score for the residual back pain was 4.1 ± 2.1, whereas the ODI was 10.5 ± 5.6 points, and the mean disability index was 21.1%. CONCLUSION: The use of bone marrow mesenchymal stem cell concentrate obtained with selective cell retention technology could be considered as an effective means for augmenting spinal fusion. LEVEL OF EVIDENCE: 3.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Yousef MAA, La Maida GA, Misaggi B, et al. Long-term Radiological and Clinical Outcomes After Using Bone Marrow Mesenchymal Stem Cells Concentrate Obtained With Selective Retention Cell Technology in Posterolateral Spinal Fusion. Spine (Phila Pa 1976). 2017. PMID: 28574883. doi:10.1097/BRS.0000000000002255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。